Filed by Bleichroeder Acquisition 2 France pursuant to Rule 425
under
the Securities Act of 1933, as amended,
and
deemed filed pursuant to Rule 14a-12
under
the Securities Exchange Act of 1934, as amended
Subject
Company: Bleichroeder Acquisition Corp. II (File No. 001-43045)
Pasqal Partners with True Nexus to Apply Quantum
Computing to Next-Generation Food Protein Design
RIYADH, Saudi Arabia & PARIS April X, 2026 - Pasqal, a global
leader in neutral-atom quantum computing, today announced a strategic collaboration with True Nexus, a computational intelligence company
focused on making protein functionality programmable for real-world food applications. Pasqal recently announced plans to go public through
a combination with Bleichroeder Acquisition Corp. II (Nasdaq: BBCQ).
The collaboration will apply Pasqal’s quantum computing technology
to one of the most persistent challenges in the alternative protein and food industries: accurately modeling and predicting protein functionality;
particularly gelatin, texture, and overall behavior in complex food systems.
“For decades, the industry has been constrained by a lack of
true computational understanding of protein behavior,” said Dominik Grabinski, CEO of True Nexus. “Partnering with Pasqal
allows us to model protein functionality at a level of fidelity that simply hasn’t been possible before. This is the breakthrough
that can shift the entire sector from trial-and-error to true design.”
As part of the collaboration, Pasqal and True Nexus are working to
build the first fully vectorized, dynamic 3D model of protein gelation, one of the most critical functional properties in food systems.
The model integrates multiple layers of data, including:
| ● | Protein extraction parameters |
| ● | Processing and environmental conditions |
| ● | End-use application requirements |
Pasqal’s neutral-atom quantum processors will enable the model
to capture interactions and variables at a level of precision not achievable with classical computing alone.
“Quantum computing allows us to tackle complexity that has limited
innovation for decades,” said Wasiq Bokhari, CEO of Pasqal. “Together with True Nexus, we’re helping enable a more scalable,
design-driven approach to sustainable protein development.”
The long-term goal of the collaboration is to establish a reference
model for protein functionality that food and ingredient companies can use to guide seed development, crop optimization, and precision
fermentation when existing proteins fall short.
The inability to consistently match animal-protein functionality has
been a major barrier to adoption of alternative proteins. By making protein behavior predictable and programmable, the collaboration between
Pasqal and True Nexus addresses a key gap that has slowed industry progress.
About Pasqal
Pasqal is a leader in the industrialization
of neutral-atom quantum computing, transforming Nobel Prize-winning research into real-world solutions for industry, science, and governments.
Since its founding in 2019, Pasqal has built high-performance quantum systems and cloud-ready software designed to address complex challenges
in optimization, simulation, and artificial intelligence.
Pasqal, headquartered in France, employs over
275 people and serves over 25 clients, including CMA CGM, OVHcloud, Thales, IBM (Pasqal is part of the IBM Quantum Network), and
Sumitomo. Backed by more than USD 300 million to date in total funding from international investors, Pasqal seeks to accelerate
the adoption of scalable, high-performance quantum computing worldwide.
Contacts
Investors
investors@pasqal.com
Media
pr@pasqal.com
About True Nexus
True Nexus is a Saudi-based computational intelligence company focused
on making protein functionality programmable. Combining artificial intelligence, advanced data infrastructure, and frontier computing
approaches, the company enables food and ingredient innovators to better understand, predict, and design protein behavior under real-world
conditions.
Its work addresses the long-standing functionality gap that has slowed
the adoption of alternative proteins across the food industry, a gap illustrated by the sector’s continued difficulty, even after
more than 20 years of effort, in replacing something as simple as gelatin in a gummy bear.
Forward-Looking Statements
Certain statements herein may be considered “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements generally are accompanied by words such as “believe,” “may,” “might”, “will,”
“estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”
“would,” ”could,” ”plan,” “predict,” “project”, ”forecast,”
“believe,” ”potential,” “seem,” “seek,” ”target,” “possible,” ”future,”
“outlook” or similar terminology or expressions that predict or indicate future events or trends. These forward-looking statements
include, but are not limited to, statements regarding future events, the proposed business combination between Bleichroeder Acquisition
Corp. II (“Bleichroeder”) and Pasqal Holding SAS (“Pasqal”), and the estimated or anticipated future results
and benefits of Pasqal’s strategic collaboration with True Nexus.
These statements are based on current expectations and are not
predictions of actual performance. They are provided for illustrative purposes only and must not be relied on as a guarantee,
prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict
and are beyond the control of Bleichroeder and Pasqal. These statements are subject to known and
unknown risks, uncertainties and assumptions regarding Pasqal’s business and the business
combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general
economic, political, social and business conditions; uncertainty or changes with respect to laws
and regulations; the inability of the parties to consummate the business combination failure to realize the anticipated
benefits of the business combination; the risk that the business combination disrupts Pasqal’s current plans and
operations; the risk from Pasqal pursuing an emerging technology, facing significant technical challenges
and the potential that it may not achieve commercialization or market acceptance; Pasqal’s reliance on
strategic partners and other third parties; Pasqal’s ability to maintain, protect and defend its intellectual
property rights; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange
Commission (the “SEC”). The foregoing list of risk factors is not exhaustive. There may be additional risks that Pasqal
and Bleichroeder presently do not know or currently believe are immaterial that could also cause actual
results to differ from those contained in forward-looking statements. In addition, forward-looking statements
provide Pasqal’s and/or Bleichroeder’s expectations, plans and forecasts of future events
and views as of the date of this communication. While Pasqal and/or Bleichroeder may elect to update these
forward-looking statements in the future, Pasqal and Bleichroeder specifically disclaim any obligation to do
so.
Additional Information and Where to Find It
The business combination will be submitted to shareholders
of Bleichroeder for their consideration. In connection with the business combination, Bleichroeder intends to file
a registration statement on Form F-4 (the “Registration Statement”) with the SEC, which will include a proxy statement/prospectus
and certain other related documents, which will serve as both the proxy statement/prospectus to be distributed to its shareholders
in connection with its solicitation for proxies for the vote by its shareholders in connection with the business combination and other
matters to be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities to be
issued to Pasqal’s shareholders in connection with the completion of the business combination. This communication is not
a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that Bleichroeder will
send to its shareholders in connection with the business combination.
BEFORE MAKING ANY INVESTMENT OR VOTING DECISION, INVESTORS AND
SECURITY HOLDERS ARE ADVISED TO READ, WHEN AVAILABLE, THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS AND,
IN EACH CASE, ANY AMENDMENTS THERETO, FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE
THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION, RELATED TRANSACTIONS AND THE PARTIES TO THE BUSINESS COMBINATION.
Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed
with the SEC free of charge at www.sec.gov.
Participants in the Solicitation
Bleichroeder, Pasqal and certain of their respective directors,
executive officers, and other members of management, employees and consultants, under SEC rules, may be deemed participants
in the solicitation of proxies from Bleichroeder’s shareholders with respect to the business combination. A list of the
names of Bleichroeder’s directors and executive officers and a description of their interests in Bleichroeder and the
business combination is contained in the sections entitled “Management,” “Principal Shareholders,” and “Certain
Relationships and Related Party Transactions” of the Final Prospectus filed by Bleichroeder with the SEC on January 8,
2026 and the Current Report on Form 8-K filed with the SEC on January 9, 2026, each of which is available free of charge at the SEC’s
website at www.sec.gov. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of
proxies from Bleichroeder’s shareholders with respect to the business combination, and their direct and indirect interests,
will be contained in the Registration Statement and the proxy statement/prospectus when they become available.
No
Offer or Solicitation
This communication is for informational purposes only and is not (i)
an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities, nor shall there be any sale, issuance
or transfer of securities in any jurisdiction in contravention of applicable law nor (ii) the solicitation of any vote in any jurisdiction
pursuant to the business combination or otherwise. No offer of securities shall be made except by means of a prospectus
meeting the requirements of Section 10 of the Securities Act of 1933 or exemptions therefrom. No securities commission or securities
regulatory authority has in any way passed upon the merits of the business combination or the accuracy or adequacy of this communication.
